-+ 0.00%
-+ 0.00%
-+ 0.00%

Shisi Pharmaceutical Group (02005): Nanofloxacin malate has been approved by the State Drug Administration and registered as an API for use in marketed formulations

Zhitongcaijing·10/29/2026 08:41:19
Listen to the news

Zhitong Finance App News, Shijiyao Group (02005) announced that the Group's nanofloxacin malate has been approved by the China National Drug Administration and registered as an active ingredient for use in marketed formulations.

Ninofloxacin malate is an anti-infective drug mainly used to treat adult community-acquired pneumonia caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus parainfluenzae, Mora catarrhalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Mycoplasma pneumoniae, and Legionella pneumophila.